Alkermes plc (8AK.F)
| Previous close | 21.00 |
| Open | 21.20 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 21.20 - 21.20 |
| 52-week range | 20.15 - 29.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 3.656B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 6.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
- PR Newswire
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
- PR Newswire
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings
